Preclinical gene therapy biotech Homology Medicines prices upsized IPO at $16 high end – Nasdaq
Nasdaq |
Preclinical gene therapy biotech Homology Medicines prices upsized IPO at $16 high end
Nasdaq Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, raised $144 million by offering 9 million shares at $16, the high end of the range of $14 to $16. It previously filed to offer 6.7 million shares … |
